Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence

Executive Summary

The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
Advertisement

Related Content

Synthetic Biologics Thinks Statins May Get At Root Of IBS-Constipation
Ironwood/Forest Hoping To Change The Conversation About Constipation
NSCLC Market Snapshot: Promising Biomarkers, Testing Challenges
Ironwood Eyes Large Market For Linaclotide, Will Tread Carefully On Price
Ironwood Eyes Large Market For Linaclotide, Will Tread Carefully On Price
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard
COPD Market Snapshot: Firms Brush Off Near-term Generic Challenges, Focus On Pipelines
RCC Market Snapshot: In A Crowded Field, What's Next?
Door Open For Zelnorm Return Despite Marketing “Suspension,” Novartis Says
Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info

Topics

Advertisement
UsernamePublicRestriction

Register

PS053558

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel